Antibodies against neuronal nicotinic receptor subtypes in neurological disorders

Barbara Balestra, Milena Moretti, Renato Longhi, Renato Mantegazza, Francesco Clementi, Cecilia Gotti

Research output: Contribution to journalArticle

Abstract

Patients with myasthenia gravis (MG) have antibodies to the muscle nicotinic acetylcholine receptor (mAChR) which are responsible for their muscle weakness: but some patients with MG and other neuroimmunological disorders have autonomic symptoms. We characterised the neuronal forms of AChRs (nAChRs) into two neuroblastoma cell lines and developed immunoprecipitation assays to test for antibodies to the α7- and α3-containing nAChR subtypes, present in the autonomic ganglia. We then tested 70 sera samples from MG patients, 38 from subjects with other neurological diseases, and 30 from healthy individuals, for antibodies to these two forms of neuronal AChR subtypes. We used the α7 subtype extracted from the human neuroblastoma IMR32 cell line labeled with 125I-αBungarotoxin (αBgtx), and the α3-containing subtype extracted from the human neuroblastoma SY5Y cell line labeled with 3H-Epibatidine (Epi). Nine subjects (five MG, one GBS, one CIPD and two LEMS) were positive for the α7 subtype; and four for the α3-containing subtype (two MG patients, one LEMS and the same GBS patient). None of the MG patients with undetectable levels of antibodies against muscle AChR were positive. The patients with serum antibodies to α7 or α3-containing neuronal AChRs showed a range of clinical features including autonomic symptoms and thymoma in two MG patients. These results indicate that patients with MG and other immune-mediated disorders can have antibodies to neuronal AChRs, and that these may contribute to the clinical characteristics of the diseases. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)89-97
Number of pages9
JournalJournal of Neuroimmunology
Volume102
Issue number1
DOIs
Publication statusPublished - Jan 3 2000

Fingerprint

Nicotinic Receptors
Nervous System Diseases
Myasthenia Gravis
Antibodies
Neuroblastoma
epibatidine
Cell Line
Autonomic Ganglia
Bungarotoxins
Muscles
Thymoma
Immune System Diseases
Muscle Weakness
Serum
Immunoprecipitation

Keywords

  • Antibodies
  • Epibatidine
  • Myasthenia gravis
  • Neuronal nicotinic receptor subtypes
  • αBungarotoxin

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Antibodies against neuronal nicotinic receptor subtypes in neurological disorders. / Balestra, Barbara; Moretti, Milena; Longhi, Renato; Mantegazza, Renato; Clementi, Francesco; Gotti, Cecilia.

In: Journal of Neuroimmunology, Vol. 102, No. 1, 03.01.2000, p. 89-97.

Research output: Contribution to journalArticle

Balestra, Barbara ; Moretti, Milena ; Longhi, Renato ; Mantegazza, Renato ; Clementi, Francesco ; Gotti, Cecilia. / Antibodies against neuronal nicotinic receptor subtypes in neurological disorders. In: Journal of Neuroimmunology. 2000 ; Vol. 102, No. 1. pp. 89-97.
@article{bba93f3788974f54b488db2641870782,
title = "Antibodies against neuronal nicotinic receptor subtypes in neurological disorders",
abstract = "Patients with myasthenia gravis (MG) have antibodies to the muscle nicotinic acetylcholine receptor (mAChR) which are responsible for their muscle weakness: but some patients with MG and other neuroimmunological disorders have autonomic symptoms. We characterised the neuronal forms of AChRs (nAChRs) into two neuroblastoma cell lines and developed immunoprecipitation assays to test for antibodies to the α7- and α3-containing nAChR subtypes, present in the autonomic ganglia. We then tested 70 sera samples from MG patients, 38 from subjects with other neurological diseases, and 30 from healthy individuals, for antibodies to these two forms of neuronal AChR subtypes. We used the α7 subtype extracted from the human neuroblastoma IMR32 cell line labeled with 125I-αBungarotoxin (αBgtx), and the α3-containing subtype extracted from the human neuroblastoma SY5Y cell line labeled with 3H-Epibatidine (Epi). Nine subjects (five MG, one GBS, one CIPD and two LEMS) were positive for the α7 subtype; and four for the α3-containing subtype (two MG patients, one LEMS and the same GBS patient). None of the MG patients with undetectable levels of antibodies against muscle AChR were positive. The patients with serum antibodies to α7 or α3-containing neuronal AChRs showed a range of clinical features including autonomic symptoms and thymoma in two MG patients. These results indicate that patients with MG and other immune-mediated disorders can have antibodies to neuronal AChRs, and that these may contribute to the clinical characteristics of the diseases. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Antibodies, Epibatidine, Myasthenia gravis, Neuronal nicotinic receptor subtypes, αBungarotoxin",
author = "Barbara Balestra and Milena Moretti and Renato Longhi and Renato Mantegazza and Francesco Clementi and Cecilia Gotti",
year = "2000",
month = "1",
day = "3",
doi = "10.1016/S0165-5728(99)00145-9",
language = "English",
volume = "102",
pages = "89--97",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "1",

}

TY - JOUR

T1 - Antibodies against neuronal nicotinic receptor subtypes in neurological disorders

AU - Balestra, Barbara

AU - Moretti, Milena

AU - Longhi, Renato

AU - Mantegazza, Renato

AU - Clementi, Francesco

AU - Gotti, Cecilia

PY - 2000/1/3

Y1 - 2000/1/3

N2 - Patients with myasthenia gravis (MG) have antibodies to the muscle nicotinic acetylcholine receptor (mAChR) which are responsible for their muscle weakness: but some patients with MG and other neuroimmunological disorders have autonomic symptoms. We characterised the neuronal forms of AChRs (nAChRs) into two neuroblastoma cell lines and developed immunoprecipitation assays to test for antibodies to the α7- and α3-containing nAChR subtypes, present in the autonomic ganglia. We then tested 70 sera samples from MG patients, 38 from subjects with other neurological diseases, and 30 from healthy individuals, for antibodies to these two forms of neuronal AChR subtypes. We used the α7 subtype extracted from the human neuroblastoma IMR32 cell line labeled with 125I-αBungarotoxin (αBgtx), and the α3-containing subtype extracted from the human neuroblastoma SY5Y cell line labeled with 3H-Epibatidine (Epi). Nine subjects (five MG, one GBS, one CIPD and two LEMS) were positive for the α7 subtype; and four for the α3-containing subtype (two MG patients, one LEMS and the same GBS patient). None of the MG patients with undetectable levels of antibodies against muscle AChR were positive. The patients with serum antibodies to α7 or α3-containing neuronal AChRs showed a range of clinical features including autonomic symptoms and thymoma in two MG patients. These results indicate that patients with MG and other immune-mediated disorders can have antibodies to neuronal AChRs, and that these may contribute to the clinical characteristics of the diseases. Copyright (C) 2000 Elsevier Science B.V.

AB - Patients with myasthenia gravis (MG) have antibodies to the muscle nicotinic acetylcholine receptor (mAChR) which are responsible for their muscle weakness: but some patients with MG and other neuroimmunological disorders have autonomic symptoms. We characterised the neuronal forms of AChRs (nAChRs) into two neuroblastoma cell lines and developed immunoprecipitation assays to test for antibodies to the α7- and α3-containing nAChR subtypes, present in the autonomic ganglia. We then tested 70 sera samples from MG patients, 38 from subjects with other neurological diseases, and 30 from healthy individuals, for antibodies to these two forms of neuronal AChR subtypes. We used the α7 subtype extracted from the human neuroblastoma IMR32 cell line labeled with 125I-αBungarotoxin (αBgtx), and the α3-containing subtype extracted from the human neuroblastoma SY5Y cell line labeled with 3H-Epibatidine (Epi). Nine subjects (five MG, one GBS, one CIPD and two LEMS) were positive for the α7 subtype; and four for the α3-containing subtype (two MG patients, one LEMS and the same GBS patient). None of the MG patients with undetectable levels of antibodies against muscle AChR were positive. The patients with serum antibodies to α7 or α3-containing neuronal AChRs showed a range of clinical features including autonomic symptoms and thymoma in two MG patients. These results indicate that patients with MG and other immune-mediated disorders can have antibodies to neuronal AChRs, and that these may contribute to the clinical characteristics of the diseases. Copyright (C) 2000 Elsevier Science B.V.

KW - Antibodies

KW - Epibatidine

KW - Myasthenia gravis

KW - Neuronal nicotinic receptor subtypes

KW - αBungarotoxin

UR - http://www.scopus.com/inward/record.url?scp=0033992081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033992081&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(99)00145-9

DO - 10.1016/S0165-5728(99)00145-9

M3 - Article

C2 - 10626672

AN - SCOPUS:0033992081

VL - 102

SP - 89

EP - 97

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1

ER -